Component
Pitavastatin
Comparator statin with comparable lipid lowering in the coenzyme Q10 crossover.
1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
Atorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol.
Experimental context and source evidence
- duration
- Crossover phases, length not stated here
- evidence_access
- Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
- experimental_model
- 19 Japanese patients with heterozygous familial hypercholesterolaemia
- exposure
- Atorvastatin 20 mg or pitavastatin 4 mg, open randomised four-phase crossover
- limitations
- Pitavastatin lowered coenzyme Q10 by 7.7 percent without reaching significance, so this is a difference in degree; no adverse events or liver or muscle enzyme abnormalities were observed with either statin, and the authors state it remains to be seen whether the change relates to long-term safety.
- organism
- 19 Japanese patients with heterozygous familial hypercholesterolaemia
- plain_language
- Atorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol.
- primary_references
- Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia. (2008). https://pubmed.ncbi.nlm.nih.gov/17957184/ DOI: 10.1038/sj.clpt.6100396
- route
- Oral
- tissue
- Plasma coenzyme Q10
Atorvastatin: mechanism of action from target occupancy to isoprenoids, transport, muscle and metabolism (2026-09-22) · lines 166–175
Original AI-assisted curation of twelve primary studies resolved by PubMed title search and cross-checked against live PubMed metadata. Findings obtained with mevastatin, simvastatin or the statin class are recorded against those subjects. Study-specific citations, doses, negative findings and limitations retained. Not publisher full text. · supports · · source_derived_draft · unverified_draft
## atorvastatin-lowers-plasma-coenzyme-q10 Atorvastatin 20 mg reduced plasma coenzyme Q10 by 26.1 percent, while pitavastatin 4 mg did not, despite comparable reductions in cholesterol. Model/species: 19 Japanese patients with heterozygous familial hypercholesterolaemia Tissue/system: Plasma coenzyme Q10 Exposure: Atorvastatin 20 mg or pitavastatin 4 mg, open randomised four-phase crossover Route: Oral Duration: Crossover phases, length not stated here Limits: Pitavastatin lowered coenzyme Q10 by 7.7 percent without reaching significance, so this is a difference in degree; no adverse events or liver or muscle enzyme abnormalities were observed with either statin, and the authors state it remains to be seen whether the change relates to long-term safety. Primary reference: Comparison of effects of pitavastatin and atorvastatin on plasma coenzyme Q10 in heterozygous familial hypercholesterolemia. (2008). https://pubmed.ncbi.nlm.nih.gov/17957184/ DOI: 10.1038/sj.clpt.6100396 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.